Updated:
Advent Life Sciences
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the...
Advent Life Sciences
Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA. It is a highly experienced team that turns break-through science into approved medicines or medical products. The firm starts and invests in early and mid-stage companies with a first-in-class or best-in-class approach, focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
General information
Firm type
Private Equity
Year founded
1981
Location
Region
Europe
Country
United Kingdom
City
London
Corporate office
London, United Kingdom
Additional offices
Boston, MA, United States · Menlo Park, CA, United States
Principals
Shahzad Malik
General Partner
Raj Parekh
General Partner
Kaasim Mahmood
General Partner
Dominic Schmidt
General Partner
Satish Jindal
General Partner
Katrine Bosley
Venture Partner
Don Drakeman
Venture Partner
Alain Huriez
Venture Partner
Majid Kazmi
Clinical Advisor
Roy Lobb
Venture Partner
Jon Moore
Operating Partner
Fraser Murray
Head of Scientific Evaluation
Ian J. Nicholson
Operating Partner
Steve Pawsey
Growth Partner
John Rex
Operating Partner
Alan E. Walts
Venture Partner
Gail Jermyn
Investor Relations Partner
Gwen O'Driscoll
Analyst
Rowena Patel
Financial Director
Victoria Smith
Financial Controller
Tom Wigmore
Financial Accountant
William Everingham
Accounts Assistant
Bonita Theara
Executive Assistant
Andrea Beesley
Team Assistant
Sector focus
Frequently asked questions
What stages does Advent Life Sciences target?
Inputs list coverage across seed, start-up, expansion, late-stage, growth and PIPE transactions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: